BD PharmingenTM FITC Rat Anti-Human IL-6

Description

Expression of IL-6 by stimulated CD14+ human monocytes. Human PBMC were stimulated for 6 hours with LPS 100 ng/ml final concentration in the presence of GolgiStop 2 muM final concentration; Cat. No. 554724 . The PBMC were harvested, stained with PE-mouse anti-human CD14 monoclonal antibody PE-M5E2, Cat. No. 555398 , fixed, permeabilized, and subsequently stained with 0.25 mug of FITC-rat anti-human IL-6 antibody Cat. No. 554544 , following Pharmingens staining protocol left panel . The data reflect gating on monocytes, based on forward and side scattered light signals. To demonstrate specificity of staining, the binding by FITC-MQ2-13A5 antibody was blocked by each of the following: 1 preincubation of the fluorochrome-conjugated antibody with molar excess of recombinant human IL-6 0.5 mug, Cat. No. 550071; middle panel and by 2 preincubation of the fixed/permeabilized cells with excess unlabeled MQ2-13A5 antibody e.g., 5 mug; Cat. No. 554543; right panel prior to staining with the FITC-MQ2-13A5 antibody. The quadrant markers for the bivariate dot plots were set based on the autofluorescence controls and verified using the recombinant cytokine blocking and unlabeled antibody blocking specificity controls. Expression of IL-6 by stimulated CD14+ human monocytes. Human PBMC were stimulated for 6 hours with LPS 100 ng/ml final concentration in the presence of GolgiStop 2 muM final concentration; Cat. No. 554724 . The PBMC were harvested, stained with PE-mouse anti-human CD14 monoclonal antibody PE-M5E2, Cat. No. 555398 , fixed, permeabilized, and subsequently stained with 0.25 mug of FITC-rat anti-human IL-6 antibody Cat. No. 554544 , following Pharmingens staining protocol left panel . The data reflect gating on monocytes, based on forward and side scattered light signals. To demonstrate specificity of staining, the binding by FITC-MQ2-13A5 antibody was blocked by each of the following: 1 preincubation of the fluorochrome-conjugated antibody with molar excess of recombinant human IL-6 0.5 mug, Cat. No. 550071; middle panel and by 2 preincubation of the fixed/permeabilized cells with excess unlabeled MQ2-13A5 antibody e.g., 5 mug; Cat. No. 554543; right panel prior to staining with the FITC-MQ2-13A5 antibody. The quadrant markers for the bivariate dot plots were set based on the autofluorescence controls and verified using the recombinant cytokine blocking and unlabeled antibody blocking specificity controls. Expression of IL-6 by stimulated CD14+ human monocytes. Human PBMC were stimulated for 6 hours with LPS 100 ng/ml final concentration in the presence of GolgiStop 2 muM final concentration; Cat. No. 554724 . The PBMC were harvested, stained with PE-mouse anti-human CD14 monoclonal antibody PE-M5E2, Cat. No. 555398 , fixed, permeabilized, and subsequently stained with 0.25 mug of FITC-rat anti-human IL-6 antibody Cat. No. 554544 , following Pharmingens staining protocol left panel . The data reflect gating on monocytes, based on forward and side scattered light signals. To demonstrate specificity of staining, the binding by FITC-MQ2-13A5 antibody was blocked by each of the following: 1 preincubation of the fluorochrome-conjugated antibody with molar excess of recombinant human IL-6 0.5 mug, Cat. No. 550071; middle panel and by 2 preincubation of the fixed/permeabilized cells with excess unlabeled MQ2-13A5 antibody e.g., 5 mug; Cat. No. 554543; right panel prior to staining with the FITC-MQ2-13A5 antibody. The quadrant markers for the bivariate dot plots were set based on the autofluorescence controls and verified using the recombinant cytokine blocking and unlabeled antibody blocking specificity controls. Show More Expression of IL-6 by stimulated CD14+ human monocytes. Human PBMC were stimulated for 6 hours with LPS 100 ng/ml final concentration in the presence of GolgiStop 2 muM final concentration; Cat. No. 554724 . The PBMC were harvested, stained with PE-mouse anti-human CD14 monoclonal antibody PE-M5E2, Cat. No. 555398 , fixed, permeabilized, and subsequently stained with 0.25 mug of FITC-rat anti-human IL-6 antibody Cat. No. 554544 , following Pharmingens staining protocol left panel . The data reflect gating on monocytes, based on forward and side scattered light signals. To demonstrate specificity of staining, the binding by FITC-MQ2-13A5 antibody was blocked by each of the following: 1 preincubation of the fluorochrome-conjugated antibody with molar excess of recombinant human IL-6 0.5 mug, Cat. No. 550071; middle panel and by 2 preincubation of the fixed/permeabilized cells with excess unlabeled MQ2-13A5 antibody e.g., 5 mug; Cat. No. 554543; right panel prior to staining with the FITC-MQ2-13A5 antibody. The quadrant markers for the bivariate dot plots were set based on the autofluorescence controls and verified using the recombinant cytokine blocking and unlabeled antibody blocking specificity controls. Show More Expression of IL-6 by stimulated CD14+ human monocytes. Human PBMC were stimulated for 6 hours with LPS 100 ng/ml final concentration in the presence of GolgiStop 2 muM final concentration; Cat. No. 554724 . The PBMC were harvested, stained with PE-mouse anti-human CD14 monoclonal antibody PE-M5E2, Cat. No. 555398 , fixed, permeabilized, and subsequently stained with 0.25 mug of FITC-rat anti-human IL-6 antibody Cat. No. 554544 , following Pharmingens staining protocol left panel . The data reflect gating on monocytes, based on forward and side scattered light signals. To demonstrate specificity of staining, the binding by FITC-MQ2-13A5 antibody was blocked by each of the following: 1 preincubation of the fluorochrome-conjugated antibody with molar excess of recombinant human IL-6 0.5 mug, Cat. No. 550071; middle panel and by 2 preincubation of the fixed/permeabilized cells with excess unlabeled MQ2-13A5 antibody e.g., 5 mug; Cat. No. 554543; right panel prior to staining with the FITC-MQ2-13A5 antibody. The quadrant markers for the bivariate dot plots were set based on the autofluorescence controls and verified using the recombinant cytokine blocking and unlabeled antibody blocking specificity controls. Expression of IL-6 by stimulated CD14+ human monocytes. Human PBMC were stimulated for 6 hours with LPS 100 ng/ml final concentration in the presence of GolgiStop 2 muM final concentration; Cat. No. 554724 . The PBMC were harvested, stained with PE-mouse anti-human CD14 monoclonal antibody PE-M5E2, Cat. No. 555398 , fixed, permeabilized, and subsequently stained with 0.25 mug of FITC-rat anti-human IL-6 antibody Cat. No. 554544 , following Pharmingens staining protocol left panel . The data reflect gating on monocytes, based on forward and side scattered light signals. To demonstrate specificity of staining, the binding by FITC-MQ2-13A5 antibody was blocked by each of the following: 1 preincubation of the fluorochrome-conjugated antibody with molar excess of recombinant human IL-6 0.5 mug, Cat. No. 550071; middle panel and by 2 preincubation of the fixed/permeabilized cells with excess unlabeled MQ2-13A5 antibody e.g., 5 mug; Cat. No. 554543; right panel prior to staining with the FITC-MQ2-13A5 antibody. The quadrant markers for the bivariate dot plots were set based on the autofluorescence controls and verified using the recombinant cytokine blocking and unlabeled antibody blocking specificity controls.